momelotinib
Ojjaara Approved for Myelofibrosis Patients With Anemia
The FDA approved momelotinib (Ojjaara, GSK) for the treatment of intermediate- or high-risk myelofibrosis, ...
SEPTEMBER 20, 2023
Data Show Momelotinib’s Value in Patients With Myelofibrosis and Anemia
New findings published in the Lancet (2023;401:269-280) suggest momelotinib (GSK) can be a valuable addition to the ...
MARCH 3, 2023
Novel JAK Inhibitor Shows Strong Efficacy in Myelofibrosis
Momelotinib, a novel oral ACVR1/ALK2 and JAK1/2 inhibitor, showed superior efficacy compared with danazol in ...
AUGUST 31, 2022
Phase 3 Study Shows Benefit of JAK Inhibitor in Symptomatic Myelofibrosis
For previously treated myelofibrosis, the novel JAK inhibitor momelotinib (GlaxoSmithKline) appears to offer a ...
JULY 8, 2022
Load more